Related Experiment Video
Updated: Aug 5, 2026
The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
Published on: November 19, 2008
Gut-brain-immune interactions in neonatal hypoxic-ischemic brain injury
Josephine Herz1,2, Ivo Bendix3,4, Frederick Orywal5
1Department of Paediatrics I, Neonatology & Experimental Perinatal Neurosciences, University Hospital Essen, University Duisburg-Essen, Essen, Germany. josephine.herz@uk-essen.de.
Insights
Neonatal hypoxia-ischemia (HI) is a major cause of disability. Emerging research highlights the gut microbiome and immune system
Area of Science:
- Neuroscience
- Immunology
- Microbiology
Background:
- Neonatal hypoxia-ischemia (HI) is a leading cause of mortality and neurodevelopmental disability in infants.
- Current treatments like therapeutic hypothermia have limited efficacy for many affected infants.
- The gut microbiome and immune system are increasingly recognized as crucial in modulating brain injury and recovery.
Purpose of the Study:
- To explore the role of the gut-brain-immune axis in neonatal HI.
- To identify potential therapeutic targets within the gut microbiome for HI.
- To understand the systemic nature of HI beyond the brain.
Main Methods:
- Review of preclinical (animal models) and clinical data on gut microbiota and immune responses in neonatal HI.
- Examination of fecal microbiota transplantation studies.
- Analysis of immune alterations in HI-affected neonates and their correlation with microbial changes.
Main Results:
- Neonatal HI induces gut dysbiosis and barrier dysfunction, linked to neuroinflammation.
- Microbial perturbations are observed in infants with hypoxic-ischemic encephalopathy (HIE).
- Peripheral immune responses are dysregulated in neonates post-HI, with some lasting effects.
Conclusions:
- Viewing neonatal HI as a systemic gut-brain-immune disease offers new therapeutic and biomarker avenues.
- Future research requires longitudinal multi-omic studies and sex-stratified analyses.
- Rigorous evaluation of microbiome-targeted interventions is essential for clinical translation.
Background:
Neonatal hypoxia-ischemia (HI) is the leading cause of childhood mortality and neurodevelopmental disability. Despite therapeutic hypothermia as the only clinically established treatment to date, outcomes remain poor for a significant proportion of affected infants. Mechanistic understanding has been brain-oriented in the past, however the gut and immune system are increasingly recognized as active modulators of brain injury, recovery and neurodevelopment.
Main Body:
Gut microbiota regulate microglial maturation, myelination and blood-brain barrier integrity. Neonatal HI induces gut dysbiosis and barrier failure, associated with neuroinflammation. First, faecal microbiota transplantation experiments in animal models suggest a causal relationship. Clinical data corroborate microbial perturbations in HIE infants, though antibiotic exposure and the NICU environment represent potential confounders. At the level of the immune system, dysregulated peripheral innate and adaptive immune responses are well documented in HI-affected neonates, with some alterations persisting into school age. The microbiota dimension of these immune responses remains largely unexplored, despite well-characterized microbiota-immune interactions in models of adult stroke. Therapeutic candidates include probiotics, human milk oligosaccharides and butyrate, each with preliminary preclinical support but no completed clinical trials in HIE.
Conclusion:
Reframing neonatal HI as a systemic gut-brain-immune disease opens up new possibilities for adjunctive therapy and biomarker discovery. Progress requires longitudinal multi-omic clinical cohorts, sex-stratified and disease-phase-resolved preclinical analyses and rigorous evaluation of microbiome-targeted interventions.
